MCID: BCT006
MIFTS: 37

Bacterial Conjunctivitis

Categories: Eye diseases, Nephrological diseases, Gastrointestinal diseases, Respiratory diseases, Cardiovascular diseases, Infectious diseases

Aliases & Classifications for Bacterial Conjunctivitis

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 14 69
Conjunctivitis, Bacterial 41
Purulent Conjunctivitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9700
ICD10 32 H10.0
MeSH 41 D003234
NCIt 46 C53656
UMLS 69 C0009768

Summaries for Bacterial Conjunctivitis

MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and cutaneous lupus erythematosus. An important gene associated with Bacterial Conjunctivitis is GCNT2 (Glucosaminyl (N-Acetyl) Transferase 2, I-Branching Enzyme (I Blood Group)), and among its related pathways/superpathways is Primary immunodeficiency. The drugs Estradiol and Norgestimate have been mentioned in the context of this disorder. Affiliated tissues include eye and testes.

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 11.4
2 cutaneous lupus erythematosus 10.0 CD40LG KRT15
3 selective igg deficiency disease 10.0 CD40LG CD79A
4 c1q nephropathy 10.0 CD40LG CD79A
5 meningovascular neurosyphilis 10.0 CD40LG CD79A
6 alpha chain disease 10.0 CD40LG CD79A
7 brill-zinsser disease 10.0 CD40LG CD79A
8 exudative glomerulonephritis 10.0 CD40LG CD79A
9 cork-handlers' disease 10.0 CD40LG CD79A
10 salpingo-oophoritis 10.0 CD40LG CD79A
11 early yaws 10.0 CD40LG CD79A
12 ventilation pneumonitis 10.0 CD40LG CD79A
13 chronic interstitial cystitis 10.0 CD40LG CD79A
14 axillary adenitis 10.0 CD40LG CD79A
15 cryofibrinogenemia 10.0 CD40LG CD79A
16 trichostrongyloidiasis 10.0 CD40LG CD79A
17 subacute bacterial endocarditis 10.0 CD40LG CD79A
18 heterophyiasis 10.0 CD40LG CD79A
19 immunoglobulin g deficiency 10.0 CD40LG CD79A
20 orbital granuloma 10.0 CD40LG CD79A
21 transient hypogammaglobulinemia of infancy 10.0 CD40LG CD79A
22 hyperglobulinemic purpura 10.0 CD40LG CD79A
23 gastroduodenitis 10.0 CD40LG CD79A
24 heavy chain disease 10.0 CD40LG CD79A
25 immunoglobulin a deficiency 1 10.0 CD40LG CD79A
26 parotid disease 10.0 CD40LG CD79A
27 cerebral arteritis 10.0 CD40LG CD79A
28 selective immunoglobulin deficiency disease 10.0 CD40LG CD79A
29 geniculate herpes zoster 10.0 CD40LG CD79A
30 erythema elevatum diutinum 10.0 CD40LG CD79A
31 sporotrichosis 10.0 CD40LG CD79A
32 fallopian tube disease 10.0 CD40LG CD79A
33 hyperimmunoglobulin syndrome 10.0 CD40LG CD79A
34 congenital syphilis 10.0 CD40LG CD79A
35 polyclonal hypergammaglobulinemia 10.0 CD40LG CD79A
36 monoclonal paraproteinemia 10.0 CD40LG CD79A
37 salpingitis 10.0 CD40LG CD79A
38 ocular toxoplasmosis 10.0 CD40LG CD79A
39 parasitic ichthyosporea infectious disease 10.0 CD40LG CD79A
40 dysgammaglobulinemia 10.0 CD40LG CD79A
41 congenital hypogammaglobulinemia 10.0 CD40LG CD79A
42 acute maxillary sinusitis 10.0 CD40LG CD79A
43 rhinosporidiosis 10.0 CD40LG CD79A
44 chronic polyneuropathy 10.0 CD40LG CD79A
45 spinocerebellar ataxia, autosomal recessive 10 10.0 CD40LG CD79A
46 cd40 ligand deficiency 10.0 CD40LG CD79A
47 secondary syphilis 10.0 CD40LG CD79A
48 yellow nail syndrome 10.0 CD40LG CD79A
49 congenital toxoplasmosis 10.0 CD40LG CD79A
50 chorioretinitis 10.0 CD40LG CD79A

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis

Symptoms & Phenotypes for Bacterial Conjunctivitis

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
2
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
3
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 151096-09-2, 354812-41-2 152946
4
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Estradiol valerate Phase 4,Phase 3,Phase 2 979-32-8
9 Fluoroquinolones Phase 4,Phase 3,Phase 2,Phase 1
10 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
11 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Contraceptive Agents Phase 4,Phase 3,Phase 2
13 Contraceptives, Oral Phase 4,Phase 3,Phase 2
14 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2
15 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
18 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
19 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
20 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
21 Polyestradiol phosphate Phase 4,Phase 3,Phase 2
22 Antibiotics, Antitubercular Phase 4,Phase 3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
24
Zinc Approved, Investigational Phase 3 7440-66-6 32051 23994
25
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
26
Tobramycin Approved, Investigational Phase 3 32986-56-4 36294 5496
27
Dipivefrin Approved Phase 3,Phase 2 52365-63-6 3105
28
Bacitracin Approved, Vet_approved Phase 3 1405-87-4 10909430 439542
29
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
30
Ephedrine Approved Phase 2, Phase 3, Phase 1 299-42-3 9294
31
Azithromycin Approved Phase 3,Phase 1 83905-01-5 53477736 447043 55185
32
Ofloxacin Approved Phase 3,Phase 2 82419-36-1 4583
33
Pseudoephedrine Approved Phase 2, Phase 3, Phase 1 90-82-4 7028
34
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
35
Levofloxacin Approved, Investigational Phase 3,Phase 2 100986-85-4 149096
36
Iodine Approved, Investigational Phase 3 7553-56-2 807
37
Vancomycin Approved Phase 3 1404-90-6 14969 441141
38
Povidone-iodine Approved Phase 3 25655-41-8
39
Povidone Approved Phase 3 9003-39-8
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
41 Polymyxin B Phase 3
42 Dexamethasone acetate Phase 3 1177-87-3
43 glucocorticoids Phase 3
44
protease inhibitors Phase 3
45 Fluprednisolone Phase 3
46 Gastrointestinal Agents Phase 3
47 HIV Protease Inhibitors Phase 3
48 Hormone Antagonists Phase 3
49 Dexamethasone, neomycin, polymyxin B drug combination Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show all 32)

# Name Status NCT ID Phase Drugs
1 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
2 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
5 Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
6 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
7 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
8 Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops;0.5% levofloxacin eye drops
9 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
10 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
11 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) Completed NCT00105469 Phase 3 AzaSite;Tobramycin
12 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) Completed NCT00105534 Phase 3 AzaSite
13 Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
14 A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
15 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
16 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
17 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
18 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
19 Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
20 Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Completed NCT01175590 Phase 3 Besivance;Vehicle
21 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
22 Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo Recruiting NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
23 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Recruiting NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
24 Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
25 Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
26 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis Completed NCT00622908 Phase 2 ISV-403;Vehicle
27 Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis Completed NCT01877694 Phase 2 Auriclosene Solution 0.3%;Auriclosene Vehicle
28 Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) Completed NCT02980523 Phase 2 PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
29 A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. Terminated NCT01928693 Phase 2 Besivance 0.6% Ophthalmic Suspension;Zymaxid 0.5% Ophthalmic Solution;Vigamox 0.5% Ophthalmic Solution
30 Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis Withdrawn NCT01238783 Phase 2 AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
31 Systemic Pharmacokinetics of BOL-303224-A Completed NCT00407589 Phase 1 BOL-303224-A
32 Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers Recruiting NCT03235141 Phase 1 azithromycin eye drops by essex;azithromycin eye drops

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: conjunctivitis, bacterial

Genetic Tests for Bacterial Conjunctivitis

Anatomical Context for Bacterial Conjunctivitis

MalaCards organs/tissues related to Bacterial Conjunctivitis:

38
Eye, Testes

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 154)
# Title Authors Year
1
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
2
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. ( 28708424 )
2017
3
Patient demographic and microbiology trends in bacterial conjunctivitis in children. ( 29247795 )
2017
4
Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. ( 29354693 )
2017
5
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. ( 28078599 )
2017
6
A chronological study of the bacterial pathogen changes in acute neonatal bacterial conjunctivitis in southern China. ( 28950852 )
2017
7
Epidemiology of bacterial conjunctivitis in chinchillas (Chinchilla lanigera): 49 cases (2005 to 2015). ( 28276116 )
2017
8
Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. ( 29131910 )
2017
9
Acute bacterial conjunctivitis - antibiotic susceptibility and resistance to commercially available topical antibiotics in Nepal. ( 28242882 )
2016
10
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. ( 28002109 )
2016
11
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. ( 25945033 )
2015
12
Deep subconjunctival injection of gentamicin for the treatment of bacterial conjunctivitis in macaques (Macaca mulatta and Macaca fascicularis). ( 25693106 )
2015
13
Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. ( 25886078 )
2015
14
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. ( 24526744 )
2014
15
Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older. ( 25244402 )
2014
16
The role of besifloxacin in the treatment of bacterial conjunctivitis. ( 24566460 )
2014
17
An evaluation of the reclassification of ophthalmic chloramphenicol for the management of acute bacterial conjunctivitis in community pharmacies in Western Australia. ( 24841453 )
2014
18
Identification of causative pathogens in eyes with bacterial conjunctivitis by bacterial cell count and microbiota analysis. ( 23246122 )
2013
19
A case of recalcitrant bacterial conjunctivitis. ( 24555257 )
2013
20
Epidemiological study of hospital-acquired bacterial conjunctivitis in a level III neonatal unit. ( 23766676 )
2013
21
External ophthalmomyiasis caused by Oestrus ovis misdiagnosed as bacterial conjunctivitis. ( 23780871 )
2013
22
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis. ( 24142473 )
2013
23
A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation study. ( 24256320 )
2013
24
Bacterial conjunctivitis. ( 22348418 )
2012
25
Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin. ( 22644963 )
2012
26
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. ( 23650458 )
2012
27
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. ( 23233796 )
2012
28
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. ( 22729919 )
2012
29
Antibiotics versus placebo for acute bacterial conjunctivitis. ( 22972049 )
2012
30
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. ( 22420526 )
2012
31
Bacterial conjunctivitis: a review of therapies and approaches. ( 23189448 )
2012
32
Bacterial conjunctivitis and of antibiotics in Dhulikhel Hospital-Kathmandu University Hospital. ( 22610873 )
2011
33
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. ( 21175242 )
2011
34
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. ( 21604820 )
2011
35
High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. ( 21988450 )
2011
36
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. ( 21573098 )
2011
37
Treatment of bacterial conjunctivitis in children. ( 21323206 )
2011
38
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. ( 22034555 )
2011
39
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. ( 21397770 )
2011
40
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. ( 22034556 )
2011
41
Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis. ( 23861618 )
2011
42
Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance. ( 20724317 )
2011
43
Bacterial conjunctivitis in children: a current review of pathogens and treatment. ( 21897142 )
2011
44
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. ( 21681652 )
2011
45
Peripheral ulcerative keratitis triggered by bacterial conjunctivitis. ( 21141332 )
2010
46
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. ( 20399984 )
2010
47
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. ( 20218747 )
2010
48
Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. ( 19935122 )
2010
49
Bacterial conjunctivitis. ( 21188158 )
2010
50
Limitations of current antibiotics for the treatment of bacterial conjunctivitis. ( 20838353 )
2010

Variations for Bacterial Conjunctivitis

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Pathways for Bacterial Conjunctivitis

Pathways related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.19 CD40LG CD79A

GO Terms for Bacterial Conjunctivitis

Biological processes related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 8.96 CD40LG CD79A
2 B cell proliferation GO:0042100 8.62 CD40LG CD79A

Sources for Bacterial Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....